<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02021266</url>
  </required_header>
  <id_info>
    <org_study_id>ICT-14070-120611-Exp Access</org_study_id>
    <nct_id>NCT02021266</nct_id>
  </id_info>
  <brief_title>Single Patient Expanded Access Protocol: Metabolic Boost</brief_title>
  <acronym>Boost</acronym>
  <official_title>Single Patient Expanded Access Protocol: Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <brief_summary>
    <textblock>
      This is a single patient expanded access protocol to investigate the effects of a second dose
      of facilitating cell-enhanced hematopoietic stem cell product.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematopoietic stem cell transplantation (HSCT) has been established as an important
      therapeutic option for patients with a variety of inherited metabolic disorders (IMD). The
      potential life-threatening complications of conventional myeloablative HSCT have limited its
      application. Additionally, conventional HSCT is only available to the small minority of
      medically suitable candidates who have histocompatibility leukocyte antigen (HLA)-identical
      siblings to donate bone marrow or mobilized peripheral blood stem cells.

      Donor mobilized peripheral blood stem cells or bone marrow will be processed via a novel
      technology to deplete mature immune cells while retaining hematopoietic stem cells (HSC) and
      graft facilitating cells (FC).

      A now-standard reduced intensity, nonmyeloablative recipient conditioning regimen will be
      used to promote mixed allogeneic chimerism, thereby significantly reducing morbidity and
      mortality.

      These two enhancements are intended to significantly improve the benefit:risk ratio of HSCT
      for patients with IMDs. If successful, transplantation will become a more feasible option for
      patients without HLA-identical siblings to donate stem cells, and could be offered to
      patients early in disease progression.

      The objective for the study is to establish chimerism following reduced intensity
      conditioning with no grade III/IV graft-versus-host disease (GVHD). The primary endpoint we
      will follow is production of the missing enzyme at ≥ 10% of the normal level at day 180
      post-transplant as for investigational new drug (IND) 14070. This expanded access protocol
      details the approach to providing a second dose of the product.
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Metachromatic Leukodystrophy</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Enriched Hematopoetic Stem Cell Infusion</intervention_name>
    <description>Enriched Hematopoetic Stem Cell Infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject was previously enrolled and qualified for transplant under IND 14070. Subject must
        be free from infection and have normal liver, kidney, heart and pulmonary function to
        proceed to a second transplant.

          1. Patient must have adequate function of other organ systems as measured by:

               -  Creatinine &lt; 2.0 mg/dl and creatinine clearance ≥60 cc/min/1.73m2. Newborns must
                  have a creatinine clearance &gt; 25 cc/min. For babies &lt; 3 months of age, the raw
                  value on GFR must be &gt; 1 cc/kg/min.

               -  Hepatic transaminases (ALT/AST) 2.5 x normal, bilirubin &lt;2.0mg/dl

               -  Normal cardiac function by echocardiogram or radionuclide scan (ejection fraction
                  or shortening fraction &gt;80% of normal value for age)

               -  Pulmonary function tests (PFT) demonstrating forced expiratory volume at one
                  second (FEV1) of &gt;50% of predicted for age. If child is too young or unable to
                  perform PFTs, crying vital capacity result of &gt;50% of normal value for age or
                  resting pulse oximeter &gt;92% on room air or clearance by pulmonologist will be
                  required.

          2. Patient, and parent, or legal guardian must have given written informed consent
             according to FDA guidelines.

          3. Patient must have a minimum life expectancy of at least 6 months.

          4. Female patients of childbearing potential cannot be pregnant or
             lactating/breast-feeding and must be either surgically sterile, postmenopausal (no
             menses for the previous 12 months), or must be practicing an effective method of birth
             control as determined by the investigator (e.g., oral contraceptives, double barrier
             methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner
             with vasectomy).

          5. Recipient screening to include glomerular filtration rate (GFR), chest X-ray (CXR),
             hepatic and renal chemistries, coagulation studies, pulmonary function testing, and
             ECHO if clinically relevant, chimerism testing, type and screen, and enzyme levels
             within 30 days of retransplant.

        Exclusion Criteria:

          1. Uncontrolled seizures, apnea, evidence of recurrent or uncontrolled aspiration, or
             need for chronic mechanical ventilation.

          2. Subject must not have had previous radiation therapy that would preclude total body
             irradiation (TBI) (as determined by radiation therapist)

          3. Uncontrolled infection or severe concomitant diseases, which in the judgment of the
             Principal Investigator, could not tolerate reduced intensity transplantation.

          4. Subject with a positive human immunodeficiency virus (HIV) antibody test result

          5. Subject who are pregnant, as indicated by a positive serum human chorionic
             gonadotropin (HCG) test

          6. Subject whose only donor is pregnant at the time of intended transplant

          7. Subject of childbearing potential who are not practicing adequate contraception as
             defined by the investigator at the site

          8. Jehovah's witnesses being unwilling to be transfused

          9. Patient that have any comorbid condition which, in the view of the Principal
             Investigators, renders the patient at too high a risk from treatment complications and
             regimen related morbidity/mortality.

         10. Insufficient funds for bone marrow processing.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Suzanne T Ildstad, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

